Biotech firm Agenus to begin Phase 1 clinical trial with AGEN1223
Category: #health  By Mateen Dalal  Date: 2020-01-10
  • share
  • Twitter
  • Facebook
  • LinkedIn

Biotech firm Agenus to begin Phase 1 clinical trial with AGEN1223

Agenus Inc., a U.S. based immuno-oncology firm, has announced that it has started dosing its first patient with AGEN1223, a novel bi-specific antibody developed to reduce regulatory T cells in the tumor microenvironment. The initial dosing was conducted in December 2019 and the study is currently ongoing, with plans to begin combinations with Agenus' investigational PD-1 inhibitor, balstilimab, in 2020.

As per reports, Dr. Anthony El-Khoueiry of the Keck School of Medicine and the USC Norris Comprehensive Cancer Center, is heading the initial dosing program as the clinical investigator. He is the Phase I program director and a renowned expert in translational medicine and early drug development with a focus in pancreatic cancers and hepatobiliary .

According to a statement, Dr. Anna Wijatyk, Head of Clinical Development, Agenus, said that the drug is an exclusive bispecific antibody created to selectively diminish certain immune-suppressive cells termed regulatory T cells. The drug’s ability to deplete such cells in the tumor microenvironment could endow a significant treatment advantage for patients suffering from cancer.

Wijatyk claims that AGEN1223 was formulated to eradicate the escape pathways of tumors, which it commonly uses to resume its growth beyond numerous lines of therapy such as anti-PD-1 therapy. Their firm believes that because of the drug’s design to both activate effector immune cells and selectively reduce intratumoral Tregs while saving peripheral Tregs, AGEN1223 could position itself as a promising combination agent and a crucial novel therapy for patients suffering through aggressive tumors.

In 2019, AGEN1223 had achieved a milestone accomplishment when the biotech’s IND filing for AGEN1223 was accepted by the FDA. The approval strengthens Agenus’s partnership with Gilead Sciences Inc. and initiates a cash payment of $7.5 million.

According to Garo H. Armen, Ph.D., Chairman & CEO, Agenus, this approval comes as the third milestone for the company during its partnership with Gilead.

Source Credit: https://investor.agenusbio.com/2020-01-08-Agenus-Commences-Phase-1-trial-with-AGEN122

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

Mateen has completed his Bachelor’s degree in electronics and telecommunication engineering, post which he lent his proficiency to the industry, working as a quality and test engineer. Drawn intricately toward the field of content creation however, Mateen soon switc...

Read More

More News By Mateen Dalal

Air France-KLM & JAL make bids to purchase stake in Malaysia Airlines
Air France-KLM & JAL make bids to purchase stake in Malaysia Airlines
By Mateen Dalal

Air France–KLM S.A., one of the leading global air transport players, has reportedly made a proposal to invest in Malaysia Airlines and gain around 49 percent stake. Japan Airlines (JAL) is also looking to acquire a 25 percent stake in Mal...

Accenture opens innovation center in South Beach Road office
Accenture opens innovation center in South Beach Road office
By Mateen Dalal

Accenture, an Irish multinational professional services company, has recently opened a global innovation center within the Accenture’s office at South Beach Road, which is supported by EDB (Economic Development Board) in Singapore. It will pro...

Verrica unveils positive data from VP-102 study in molluscum treatment
Verrica unveils positive data from VP-102 study in molluscum treatment
By Mateen Dalal

Findings from the study are being produced at the 17th Annual Winter Clinical Dermatology Conference in Kohala Coast The data indicated a considerable increase in the percentage of patients with lesion clearance in VP-102 group Verrica Pharmaceu...